Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calixa Therapeutics Inc.

Division of Merck & Co. Inc.
www.calixainc.com

Latest From Calixa Therapeutics Inc.

Domain and Adynxx CEO Orr engineer another venture exit as Cubist options pain drug

If the recently initiated Phase II trial for Adynxx's post-surgical pain drug AYX1 is successful, the San Francisco-based company's CEO Rick Orr and Domain Associates partner Dennis Podlesak will complete their fifth successful exit for venture capital investors in an entrepreneurial biotechnology firm.

Cardiovascular Orthopedics

Will New Antibiotic Incentives GAIN Investors’ Backing?

The GAIN Act is intended to spur development of new antibiotics, but incentives like extended market exclusivity and priority review, while important benefits, may not be enough to get investors off the sidelines.

BioPharmaceutical Clinical Trials

Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth

Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.

Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth

Cubist has focused on marketing its sole drug, Cubicin, since the antibiotic was approved in 2003, but through business development and clinical progress, the biopharma is in the midst of a transformation.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Dennis Podlesak, CEO
    Lynne R Rollins, CFO
    James Ge, PhD, MD, EVP, CSO
  • Contact Info
  • Calixa Therapeutics Inc.
    Phone: (858) 480-2420
    12481 High Bluff Dr., Ste. 150
    San Diego, CA 92130
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register